Standout Papers
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial (2019)
- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) (2021)
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC (2018)
- m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade (2019)
Immediate Impact
11 from Science/Nature 54 standout
Citing Papers
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Tumour vasculature at single-cell resolution
2024 StandoutNature
Works of Yu Deng being referenced
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Yu Deng | 2111 | 746 | 548 | 3686 | 2458 | 154 | 7.4k | |
| Marcello Maggiolini | 5459 | 731 | 395 | 2447 | 727 | 203 | 11.7k | |
| Tetsuya Taguchi | 3699 | 205 | 275 | 3026 | 861 | 285 | 9.3k | |
| Sari Mäkelä | 2740 | 799 | 420 | 1280 | 815 | 108 | 8.1k | |
| V. Craig Jordan | 3985 | 628 | 143 | 3249 | 605 | 156 | 11.1k | |
| Yatrik M. Shah | 4930 | 221 | 856 | 1670 | 1169 | 167 | 10.1k | |
| Hideyo Sato | 4559 | 227 | 541 | 839 | 1786 | 96 | 7.9k | |
| Daniel S. Longnecker | 2320 | 147 | 205 | 5218 | 537 | 175 | 8.9k | |
| Frederick E. Domann | 4883 | 276 | 516 | 1097 | 648 | 162 | 7.7k | |
| Antonino Belfiore | 6512 | 140 | 187 | 2627 | 785 | 210 | 12.7k | |
| Ralph Buttyan | 3876 | 76 | 157 | 1650 | 2386 | 110 | 7.5k |
All Works
Loading papers...